Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Abstract B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is ofte...

Full description

Bibliographic Details

Main Authors:	Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, Erin Hertlein
Format:	Artigo
Language:	Inglês
Published:	BMC 2021-02-01
Series:	Journal of Hematology & Oncology
Subjects:	Chronic lymphocytic leukemia Hsp90 BTK
Online Access:	https://doi.org/10.1186/s13045-021-01039-9
Tags:	Add Tag No Tags, Be the first to tag this record!